These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30322792)

  • 1. Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns.
    Habib LA; Kuo KHM; Panzarella T; Gupta V; Trinkaus M
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e37-e42. PubMed ID: 30322792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns.
    Streiff MB; Smith B; Spivak JL
    Blood; 2002 Feb; 99(4):1144-9. PubMed ID: 11830459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.
    Jentsch-Ullrich K; Eberhardt J; Zeremski V; Koehler M; Wolleschak D; Heidel FH
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):2041-9. PubMed ID: 27431664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era.
    Kander EM; Moliterno AR; Rademaker A; Streiff MB; Spivak JL; Stein BL
    J Natl Compr Canc Netw; 2016 Oct; 14(10):1238-1245. PubMed ID: 27697978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive treatment patterns among US veterans with polycythemia vera.
    Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L; Baser O; Scherber R
    BMC Cancer; 2018 May; 18(1):528. PubMed ID: 29728092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
    Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
    Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
    Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology.
    Jakovic L; Gotic M; Gisslinger H; Soldatovic I; Sefer D; Tirnanic M; Lekovic D; Jovanovic MP; Schalling M; Gisslinger B; Beham-Schmid C; Simonitsch-Klupp I; Thiele J
    Ann Hematol; 2018 Sep; 97(9):1581-1590. PubMed ID: 29717365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycythemia Vera.
    Spivak JL
    Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.
    Scherber RM; Geyer HL; Dueck AC; Kosiorek HE; Finazzi G; Cavazzina R; Masciulli A; Scarano M; Vannucchi AM; Mesa RA; Barbui T
    Leuk Lymphoma; 2017 Jun; 58(6):1481-1487. PubMed ID: 27830999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines.
    Jackson Chornenki NL; Chai-Adisaksopha C; Leong DP; Siegal DM; Hillis CM
    Leuk Res; 2018 Jul; 70():62-66. PubMed ID: 29885533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
    Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97).
    Felser S; Rogahn J; Hollenbach L; Gruen J; le Coutre P; Al-Ali HK; Schulze S; Muegge LO; Kraze-Kliebhahn V; Junghanss C
    Cancer Med; 2023 Sep; 12(17):18235-18245. PubMed ID: 37559463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey.
    Devos T; Beguin Y; Noens L; Van Eygen K; Zachée P; Mineur P; Knoops L; Doyen C; Theunissen K; Benghiat FS; Reusens M; Pluymers W
    Eur J Haematol; 2018 Apr; 100(4):361-366. PubMed ID: 29285836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.
    Kondo T; Okuno N; Naruse H; Kishimoto M; Tasaka T; Tsujioka T; Matsuoka A; Sugihara T; Tohyama Y; Tohyama K
    Leuk Lymphoma; 2008 Sep; 49(9):1784-91. PubMed ID: 18661406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.
    Means RT
    Am J Med Sci; 2008 Oct; 336(4):327-9. PubMed ID: 18854675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chinese expert consensus on the comprehensive management of thromboembolism in polycythemia vera].
    Myelodysplastic Syndrome/Myeloproliferative Neoplasms Association Affiliated to Chinese Medicine Education Association
    Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(5):319-328. PubMed ID: 36740389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.